AbbVie's Q2 Results Expected to be Inline With Expectations, RBC Says
AbbVie's (ABBV) Q2 financial results are expected to be in line with expectations, RBC Capital Markets analysts said in a Friday note. The company is scheduled to report its Q2 financial results on July 31. Analysts said sentiment on AbbVie has changed significantly, especially after the recent Apogee deal, which addresses a primary overhang for the stock. RBC lowered its adjusted earnings per share estimate for the company to $3.57 from $3.76. Analysts polled by FactSet expect $3.70. RBC maintained an outperform rating on the stock and increased its price target to $280 from $260.
AbbVie's (ABBV) Q2 financial results are expected to be in line with expectations, RBC Capital Markets analysts said in a Friday note.
The company is scheduled to report its Q2 financial results on July 31.
Analysts said sentiment on AbbVie has changed significantly, especially after the recent Apogee deal, which addresses a primary overhang for the stock.
RBC lowered its adjusted earnings per share estimate for the company to $3.57 from $3.76.
Analysts polled by FactSet expect $3.70.
RBC maintained an outperform rating on the stock and increased its price target to $280 from $260.